

18 March 2026

Biological Treatments for Melanoma

I have a freedom of information request regarding the treatment of melanoma. Could you please answer the following questions:

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- **Cobimetinib** 0
- **Dabrafenib** <5
- **Dabrafenib + Trametinib** 17
- **Dacarbazine** 0
- **Denosumab** 0
- **Encorafenib + Binimetinib** 29
- **Ipilimumab monotherapy** 0
- **Ipilimumab + Nivolumab** 8
- **Nivolumab monotherapy** 10
- **Nivolumab + Relatlimab** <5
- **Pembrolizumab** 39
- **Trametinib** 0
- **Vemurafenib** 0
- **Vemurafenib + Cobimetinib** 0
- **Other active systemic anti-cancer therapy Tebentafusp** <5
- **Palliative care only** Not recorded on RISOH

Q2. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

- **Ipilimumab (monotherapy)** 0
- **Nivolumab (monotherapy)** 0
- **Nivolumab AND Ipilimumab (combination)** 7
- **Nivolumab AND Relatlimab** 0
- **Pembrolizumab** 8
- **Any Targeted Therapy (Dabrafenib- <5 /Dabrafenib AND Trametinib- <5 /Encorafenib AND Binimetinib- <5 /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)**
- **Other active systemic anti-cancer therapy** 0

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.